Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of medicine for treating dilated cardiomyopathy and its screening and preparation method

A dilated cardiomyopathy and drug technology, applied in biochemical equipment and methods, pharmaceutical formulations, drug combinations, etc., can solve the problem that is poorly understood, the relationship between viral miRNAs and dilated cardiomyopathy has not been reported, and there is no viral miRNAs treatment Drug and other problems, to achieve the effects of easy detection, improvement of the connection function between vascular endothelial cells, and overcoming the problem of drug resistance

Active Publication Date: 2020-09-25
TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether miRNAs expressed by viruses are involved in the disease process caused by viruses, and by what mechanism, are still poorly understood.
In the research related to chronic dilated cardiomyopathy, although the expression profile of miRNAs in the peripheral blood of patients has been detected (Circulation. -6), but the relationship between viral miRNAs and dilated cardiomyopathy has not been reported, and there is no therapeutic drug targeting viral miRNAs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of medicine for treating dilated cardiomyopathy and its screening and preparation method
  • A kind of medicine for treating dilated cardiomyopathy and its screening and preparation method
  • A kind of medicine for treating dilated cardiomyopathy and its screening and preparation method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] A drug for treating dilated cardiomyopathy, the drug's active ingredients include kshv-miR-K12-1-5p as a drug target, and express the kshv-miR by binding, degrading, and / or down-regulating -K12-1-5p substances, thereby playing a role in the treatment of dilated cardiomyopathy. Through the experiment of Experimental Example 1, it was found that kshv-miR-K12-1-5p can be used as a drug target, but because KSHV infection is species and tissue specific, it only infects humans and does not infect animals, so it is impossible to prepare animals infected by the virus Model. For therapeutic purposes in dilated cardiomyopathy, experiments were therefore further performed using human-derived endothelial cell lines, which could result in endothelial cell-to-endothelial junctions by stimulation with kshv-miR-K12-1-5p complex or direct infection with KSHV Functional disorder and barrier function damage, and by degrading kshv-miR-K12-1-5p, and / or down-regulating the expression of ksh...

Embodiment 2

[0043] A method for screening drugs for the treatment of dilated cardiomyopathy, by detecting whether a candidate substance can bind, degrade, and / or down-regulate the expression of kshv-miR-K12-1-5p; - A substance that inhibits the expression of K12-1-5p.

[0044] For the specific experimental operation steps of this group of embodiments, please refer to Experimental Example 2.

Embodiment 3

[0046] A method for preparing a drug for treating dilated cardiomyopathy, comprising: using a substance capable of binding, degrading, and / or down-regulating the expression of kshv-miR-K12-1-5p as the activity of a drug for treating dilated cardiomyopathy Element.

[0047] In a preferred embodiment, the substance that down-regulates the expression of kshv-miR-K12-1-5p comprises a sequence fragment kshv-miR-K12-1-5p-inhibitor that is antisense complementary to kshv-miR-K12-1-5p , the antisense complementary sequence fragment is shown in SEQID NO.2.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicine for treating dilated cardiomyopathy as well as a screening and preparation method thereof, which belong to the field of medical bioengineering. The medicinal component of the medicine comprises kshv-miR-K12-1-5p as a drug target, the substance of the kshv-miR-K12-1-5p is subjected to binding, degrading, and / or down-regulated expression. The medicine takes kshv-miR-K12-1-5p as a drug target, can significantly improve the intercellular junctional dysfunction caused by KSHV infection and damage due to barrier action by down-regulated expression of kshv-miR-K12-1-5p molecules, and potentially improves the function of the heart.

Description

technical field [0001] The present invention relates to a drug for treating dilated cardiomyopathy and its screening and preparation methods, in particular to a new medical application of an antisense complementary sequence of acquired viral non-coding small RNA, more specifically to a The use of non-coding kshv-miR-K12-1-5p antisense complementary sequence in the treatment of dilated cardiomyopathy and the screening and preparation method of drugs containing the non-coding kshv-miR-K12-1-5p antisense complementary sequence, It belongs to the field of medical bioengineering. Background technique [0002] Chronic dilated cardiomyopathy is a clinical syndrome that develops to the end stage of different cardiovascular diseases. The main pathophysiological features are impaired ventricular filling and ejection ability, which eventually leads to low ventricular pumping function. It has a poor prognosis and high mortality. , is one of the most important causes that threaten human...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6883A61K45/00A61P9/00
Inventor 汪道文赵艳茹陈琛文铮
Owner TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com